Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Yap1 Mediates Trametinib Resistance in Head and Neck Squamous Cell Carcinomas

5 Feb 2021

Abstract excerpt

PURPOSE: In a head and neck squamous cell carcinoma (HNSCC) "window of opportunity" clinical trial, we reported that trametinib reduced MEK-Erk1/2 activation and resulted in tumor responses in a subset of patients. Here, we investigated resistance to trametinib and molecular correlates in HNSCC cell lines and patient samples. EXPERIMENTAL DESIGN: HNSCC cell lines were treated with trametinib to generate resistant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to Hippo pathway signaling and YAP/TAZ
Share to Melanoma and MAPK Pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33547198
DOI: 10.1158/1078-0432.ccr-19-4179

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Yap1 Mediates Trametinib Resistance in Head and Neck Squamous Cell CarcinomasPMID 33547198Read ↗

YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling.Semantic proximity Read ↗

MAP2K1 is a potential therapeutic target in erlotinib resistant head and neck squamous cell carcinoma.Semantic proximity Read ↗

The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.Semantic proximity Read ↗

Integrated single-cell and bulk gene expression and ATAC-seq reveals heterogeneity and early changes in pathways associated with resistance to cetuximab in HNSCC-sensitive cell linesSemantic proximity Read ↗

CRISPR screens reveal YAP/TEAD axis as a mediator of drug-tolerant cells in EGFR-mutant NSCLC.Semantic proximity Read ↗

CRISPR Screens Reveal YAP/TEAD Axis as a Mediator of Drug-Tolerant Cells in EGFR- Mutant NSCLCSemantic proximity Read ↗

Genome-wide CRISPR screens identify the YAP/TEAD axis as a driver of persister cells in EGFR mutant lung cancer.Semantic proximity Read ↗

FGFR3-TACC3 fusion proteins act as naturally occurring drivers of tumor resistance by functionally substituting for EGFR/ERK signalingSemantic proximity Read ↗

YAP/TAZ mediates resistance to KRAS inhibitors through inhibiting proapoptosis and activating the SLC7A5/mTOR axis.Semantic proximity Read ↗

A chemical genetic screen identifies Aurora kinases as a therapeutic target in EGFR T790M negative, gefitinib-resistant head and neck squamous cell carcinoma (HNSCC).Semantic proximity Read ↗

Dual inhibition of HERs and PD-1 counteract resistance in KRASG12C-mutant head and neck cancer.Semantic proximity Read ↗

HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.